NEW YORK, December 9, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), ARCA biopharma, Inc. (NASDAQ: ABIO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Gilead Sciences Inc. Research Report
On December 4, 2013, Gilead Sciences Inc.'s (Gilead) stock increased 0.07%, closing the day's session at $72.47. During the past three trading days, the Company's stock ended 3.13% lower compared to the Dow Jones Industrial Average Index which ended 1.22% lower over the same three trading sessions. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Oculus Innovative Sciences, Inc. Research Report
On December 4, 2013, Oculus Innovative Sciences, Inc. (Oculus) announced that it has received a new 510(k) clearance from the US Food and Drug Administration (FDA) for the Company's new Microcyn® Scar Management HydroGel. According to the Company, the Rx product, under the supervision of a healthcare professional, is intended for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures and trauma wounds. Additionally, the Company stated that its US dermatology partner, Quinnova Pharmaceuticals, intends to commercialize the product in H1 2014. Commenting on the news, Jim Schutz, Oculus' CEO said, "We are pleased to receive this scar management 510(k) clearance, which is the eighth FDA approval or clearance for our Microcyn-based products to date. We believe that Quinnova's dermatology sales and marketing expertise, and our strong supporting clinical data for this new product, is a winning combination for doctors and their patients. We look forward to sharing this new FDA clearance with our international partners to make this great product available outside the United States as soon as we clear international regulatory hurdles." The Full Research Report on Oculus Innovative Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ARCA biopharma, Inc. Research Report
On November 21, 2013, ARCA biopharma, Inc. (ARCA) announced that John L. Zabriskie, Ph.D., has resigned from the Company's Board of Directors, effective November 19, 2013. According to the Company, Dr. Zabriskie has served as a member of ARCA's Board of Directors since March 2005. Michael Bristow, M.D., Ph.D., President and CEO of ARCA, stated, "I want to express our deep gratitude and appreciation for John's contributions to ARCA and the Board. John has been a tremendous asset, sharing his extensive experience and wisdom from a highly successful career in our industry. We will miss his sage advice and steady hand in guiding the Company." The Full Research Report on ARCA biopharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Arena Pharmaceuticals, Inc. Research Report
On December 4, 2013, Arena Pharmaceuticals, Inc.'s (Arena Pharmaceuticals) stock declined 1.06% to end the trading session at $6.53. However, over the previous three trading days, the Company's stock increased 0.15%, compared to the Nasdaq composite Index which ended 0.54% lower during the same trading period. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Tonix Pharmaceuticals Holding Corp Research Report
On November 26, 2013, Tonix Pharmaceuticals Holding Corp (Tonix Pharmaceuticals) announced that it will make a presentation at the 24th Annual Oppenheimer Healthcare Conference, to be held in New York City. According to the Company, Seth Lederman, M.D., President and CEO of Tonix Pharmaceuticals, will deliver a corporate overview at the event, at 3:55 p.m. ET, on Tuesday, December 10, 2013. Lederman stated, "We are developing TNX-102 SL with the goal of offering an important new therapeutic option for fibromyalgia patients, and remain on track to announce results from the BESTFIT trial in the second half of next year. Of note, and also taking place on December 10, the Food and Drug Administration will hold its Fibromyalgia Public Meeting on Patient-Focused Drug Development in Silver Spring, MD. This meeting is intended to allow the FDA to obtain patients' perspectives on the impact of fibromyalgia on their daily lives, as well as on the available therapies for this syndrome. We believe this event will reaffirm the value of our development program and tell an important part of the Tonix story to investors." The Full Research Report on Tonix Pharmaceuticals Holding Corp - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner